Presage Biosciences

Presage Biosciences is pioneering a novel approach to cancer drug development with its CIVO platform, a translational tool that allows for the safe, simultaneous testing of multiple microdosed therapies in a single patient's tumor. This technology bridges a critical gap between preclinical models and clinical trials by providing high-resolution, spatial data on molecular and cellular responses in the actual human tumor microenvironment. The company operates both a preclinical services business and has advanced the platform into clinical studies with pharmaceutical partners. Its mission is to de-risk and accelerate oncology drug development by delivering more predictive human data early in the process.

CIVO (Comparative In Vivo Oncology) platform: a patented intratumoral microdosing and analysis system that enables simultaneous, localized testing of multiple drugs or combinations in a single living tumor, followed by spatial molecular profiling of the tumor microenvironment response.

Presage operates in a niche with few direct competitors. Traditional competitors include contract research organizations (CROs) offering preclinical in vivo testing, but they lack the human intratumoral multiplexing capability. Indirect competition comes from pharmaceutical companies' internal translational medicine departments and other emerging technologies like organoids or complex in vitro models, though these lack the full in vivo human TME context CIVO provides.